Improvement of mouse β-thalassemia upon erythropoietin delivery by encapsulated myoblasts
Authors:
- E PayenEPE Payen
- E RegulierERE Regulier
- N DeglonNDN Deglon
- P Rouyer-FessardPRP Rouyer-Fessard
- Y BeuzardYBY Beuzard
- P AebischerPAP Aebischer
- 1 February 1999
- journal article
- Published by Springer Nature in Gene Therapy
- Vol. 6 (2) , 157-161
Abstract
At the forefront of medicine, Gene Therapy brings you the latest research into genetic and cell-based technologies to treat disease. It also publishes Progress & Prospects reviews and News and Commentary articles, which highlight the cutting edge of the field.Keywords
This publication has 24 references indexed in Scilit:
- A mouse model for beta 0-thalassemia.Proceedings of the National Academy of Sciences, 1995
- Mouse model of human beta zero thalassemia: targeted deletion of the mouse beta maj- and beta min-globin genes in embryonic stem cells.Proceedings of the National Academy of Sciences, 1995
- Improvement of mouse β thalassaemia by hydroxyureaBritish Journal of Haematology, 1993
- Augmentation by Erythropoietin of the Fetal-Hemoglobin Response to Hydroxyurea in Sickle Cell DiseaseNew England Journal of Medicine, 1993
- Improvement of mouse beta-thalassemia by recombinant human erythropoietinBlood, 1991
- The role of membrane skeletal-associated alpha-globin in the pathophysiology of beta-thalassemiaBlood, 1990
- Stimulation of Fetal Hemoglobin Synthesis by Erythropoietin in BaboonsNew England Journal of Medicine, 1987
- Attempts at Gene Therapy in β‐Thalassemic MiceAnnals of the New York Academy of Sciences, 1985
- A mouse model for β-thalassemiaCell, 1983
- Electrophoretically detected germinal mutations induced in the mouse by ethylnitrosourea.Proceedings of the National Academy of Sciences, 1981